repurposing semaglutide and liraglutide for alcohol use disorder A new clinical trial supported by the National Institutes of Health (NIH) found that a medication commonly used weight loss, such as semaglutide, may also help reduce heavy drinking in individuals GLP-1 receptor agonists for the

The only described case of combination therapy with naltrexone/bupropion for 6 months showed an improvement of eating habits, without a significant reduction of BMI in an adolescent girl with PWS [61]

5.6 CRISPR-Cas9 and genomic correction CRISPR-Cas9 enables precise genome editing and holds transformative potential for monogenic PD, particularly: Correction of LRRK2 G2019S , SNCA triplications, or PINK1 mutations

Common side effects of IV therapy can include bruising or soreness at the injection site, and in rare cases, infections

Reduce adverse drug reactions

The slowed gastric emptying also helps moderate postprandial glucose excursions and may reduce the glycemic impact of meals

Potential Drug Interactions While the combination of GLP-1 agonists and hormonal treatments appears promising, it is essential to consider potential drug interactions